Bosworth Hayden B, Ngouyombo Barbara, Liska Jan, Zullig Leah L, Atlani Caroline, Beal Anne C
Center for Health Services Research in Primary Care, Durham Veterans Affairs Health Care System, Durham, NC, USA.
Department of Population Health Sciences, Duke University, Durham, NC, USA.
Patient Prefer Adherence. 2018 Mar 6;12:341-348. doi: 10.2147/PPA.S153766. eCollection 2018.
Lipid-lowering medications have been shown to be efficacious, but adherence is suboptimal. This is a narrative, perspective review of recently published literature in the field of medication adherence research for lipid-lowering medications. We provide an overview of the impact of suboptimal adherence and use a World Health Organization framework (patient, condition, therapy, socioeconomic, and health system-related systems) to discuss factors that influence hyperlipidemia treatment adherence. Further, the review involves an evaluation of intervention strategies to increase hyperlipidemia treatment adherence with a special focus on mHealth interventions, patient reminders on packaging labels, nurse- and pharmacist-led interventions, and health teams. It also highlights opportunities for pharmaceutical companies to support and scale such behavioral interventions. Medication adherence remains a challenge for the long-term management of chronic conditions, especially those involving asymptomatic disease such as hyperlipidemia. To engage patients and enhance motivation over time, hyperlipidemia interventions must be targeted to individual patients' needs, with sequencing and frequency of contact tailored to the various stages of behavioral change.
降脂药物已被证明是有效的，但依从性并不理想。这是一篇叙述性的、观点性的综述，回顾了降脂药物药物依从性研究领域最近发表的文献。我们概述了依从性欠佳的影响，并使用世界卫生组织的框架（患者、病情、治疗、社会经济和卫生系统相关因素）来讨论影响高脂血症治疗依从性的因素。此外，本综述还评估了提高高脂血症治疗依从性的干预策略，特别关注移动健康干预、包装标签上的患者提醒、护士和药剂师主导的干预以及健康团队。它还强调了制药公司支持和推广此类行为干预措施的机会。药物依从性仍然是慢性病长期管理中的一个挑战，尤其是那些涉及无症状疾病（如高脂血症）的情况。为了随着时间的推移让患者参与进来并增强其积极性，高脂血症干预措施必须针对个体患者的需求，根据行为改变的不同阶段调整接触的顺序和频率。
